Skip to main
ZYME

Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks Inc (ZYME) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zymeworks is a clinical-stage biopharmaceutical company that has a positive outlook due to its suite of therapeutic platforms and fully integrated drug development engine, which allows for precise engineering of differentiated therapeutic product candidates. The company's lead clinical candidate, zanidatamab, is currently being evaluated in multiple clinical trials and has shown promising results. The company's pivot to a core royalty aggregation model, with potential partnerships for its programs, as well as its differentiated royalty creation strategy, also contribute to its positive outlook. However, clinical trial risk remains a key concern as the company's valuation is highly dependent on the success of its pipeline assets.

Bears say

Zymeworks is currently facing numerous challenges including clinical trial failures, commercial and biotech sector risk, and financing risks due to its capital-intensive nature. A recent financing deal with Royalty Pharma and positive clinical trial results for its candidate drug zanidatamab may provide some short-term benefits, but overall, the company's lack of differentiation and uncertainties surrounding its pipeline pose long-term concerns and warrant a negative outlook on its stock.

Zymeworks Inc (ZYME) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zymeworks Inc (ZYME) Forecast

Analysts have given Zymeworks Inc (ZYME) a Buy based on their latest research and market trends.

According to 10 analysts, Zymeworks Inc (ZYME) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zymeworks Inc (ZYME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.